Payers and health technology appraisal (HTA) bodies are calling for the European Commission’s reform of the EU pharmaceutical legislation to include requirements for providing comparative data but to reject more pandemic-style rolling reviews and transferable exclusivity vouchers. However, there are doubts about whether the commission will take on the suggestions, said speakers at a recent webinar on 13 July.
Payers and HTA bodies gave more details on their wish list for what should be included in the commission’s overhaul...







